Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20027683 | 0.84 | CAPN1 (0.56) | CAPN1CTSS | |
| SCHEMBL30133581 | 0.84 | CAPN1 (0.56) | CAPN1CTSS | |
| SCHEMBL22895586 | 0.82 | CAPN1 (0.58) | CAPN1CTSS | |
| SCHEMBL22896293 | 0.81 | CAPN1 (0.53) | CAPN1CTSS | |
| SCHEMBL22896087 | 0.80 | CAPN1 (0.56) | CAPN1CTSS | |
| SCHEMBL22896712 | 0.79 | CAPN1 (0.52) | CAPN1CTSS | |
| SCHEMBL22896194 | 0.79 | CAPN1 (0.52) | CAPN1CTSS | |
| SCHEMBL22896066 | 0.79 | CAPN1 (0.52) | CAPN1CTSS | |
| SCHEMBL22896055 | 0.79 | CAPN1 (0.52) | CAPN1CTSS | |
| SCHEMBL22896296 | 0.79 | CAPN1 (0.51) | CAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSS 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.